Inhibitory Effects of Yuzu and Its Components on Human Platelet Aggregation.
10.4062/biomolther.2015.011
- Author:
Tae Ho KIM
1
;
Hye Min KIM
;
Se Won PARK
;
Yi Sook JUNG
Author Information
1. College of Pharmacy, Ajou University, Suwon 443-749, Republic of Korea. yisjung@ajou.ac.kr
- Publication Type:Original Article
- Keywords:
Yuzu;
Hesperidin;
Naringin;
Platelet;
Aggregation
- MeSH:
Adenosine Diphosphate;
Animals;
Bleeding Time;
Blood Platelets;
Ethanol;
Hesperidin;
Humans;
Mice;
Phosphorylation;
Platelet Aggregation*;
Platelet-Rich Plasma;
Rats;
Tail
- From:Biomolecules & Therapeutics
2015;23(2):149-155
- CountryRepublic of Korea
- Language:English
-
Abstract:
Our previous study demonstrated that yuzu has an anti-platelet effect in rat blood. In the present study, we examined whether the anti-platelet effect of yuzu can be extended to human blood by investigating its ability to inhibit aggregations induced by various agonists in human platelet rich plasma (PRP). This study also investigated the underlying mechanism of yuzu focusing on ADP granule secretion, TXB2 formations, and PLCgamma/Akt signaling. The results from this study showed that ethanolic yuzu extract (YE), and its components, hesperidin and naringin, inhibited human platelet aggregation in a concentration-dependent manner. YE, hesperidin and naringin also inhibited TXB2 formation and ADP release. The phosphorylation of PLCgamma and Akt was significantly inhibited by YE, heperidin and naringin. Furthermore, we demonstrated that YE, heperidin and naringin has anti-platelet effects in rat ex vivo studies, and lower side effects in mice tail bleeding time studies. The results from this study suggest that YE, hesperidin and naringin can inhibit human platelet aggregation, at least partly through the inhibition of PLCgamma and Akt, leading to a decrease in TXB2 formation and granule secretion.
